maxicuma
  • Technology
  • Science
    • Pharmacokinetic Study
    • Preclinical Study
    • Joint Health
  • Benefits
  • Resources
    • Newsroom
      • Events
      • Media and Publications
      • Podcasts
  • About Us
  • FAQs
  • Blog
  • Contact & Support
maxicuma
  • ABOUT US
  • FAQs
  • BLOG
  • CONTACT & SUPPORT
  • Technology
  • Science
    • Pharmacokinetic Study
    • Preclinical Study
    • Joint Health
  • Benefits
  • Resources
    • Newsroom
      • Events
      • Media and Publications
      • Podcasts
      • Blog

Why to choose

  • Ideal 1-A-Day dose
  • Formulation Possibilities
  • Self-GRAS Affirmed
  • Patent and Trademark

Ideal 1-A-Day dose

Maxicuma® is formulated using our proprietary LIMAN™ technology for enhanced solubility, absorption, and bioavailability thereof, as a result, Maxicuma® supports joint health at lower doses of 100–250 mg per day, compared to standard curcumin 95% (micronized).

Benefits-Capsules-Updated-min

Consistent Efficacy

Maxicuma® is clinically studied to reduce the symptoms associated with the joint discomfort and improve the physical performance consistently throughout the supplementation period.

  • Maxicuma® 100 mg
  • Maxicuma® 250 mg
Vas--min
  • Maxicuma® 100 mg
  • Maxicuma® 250 mg
Womac--min

Delivering Better Value

At 250 mg daily dosing for joint health, MaxiCuma® delivers superior efficacy at a better cost value proposition, compared to other curcumin options available in the market as given below:

2.5 X
Standard Extract
3.6 X
1st Generation
(Using Adjuvant like Piperine)
3.8 X
2nd Generation 
(Using Phospholipids)
2.6 X
3rd Generation
(Using Synthetic Emulsifier)

Versatile Application Formats

The cold water dispersibility and a neutral taste profile achieved using LIMAN™ technology make Maxicuma® ideal for a range of applications, including:

01-Shots-min
Shots
02-Capsules-min
Capsules
03-Gummies-min
Gummies
04-Tablets-min
Tablets
05-Protien-Bars-min
Protein Bars
06-RTD--min
Ready to Drink
01
01-Shots-min
Shots
02
02-Capsules-min
Capsules
03
03-Gummies-min
Gummies
04
04-Tablets-min
Tablets
05
05-Protien-Bars-min
Protein Bars
06
06-RTD--min
Ready to Drink

Self-GRAS Affirmed

Self---GRAS-Affirmed-min

Maxicuma® was evaluated for safety through acute single and repeated dose toxicity studies. 2 preclinicals and safety studies have been conducted to evaluate the safety of Maxicuma®, and two clinical trials have been conducted without any adverse events. Further, it is certified for self-affirmed GRAS (Generally Recognized as Safe) by convening a scientific expert review panel. The GRAS dosage for functional food and beverages is 50 mg per serving.

Patent and Trademark

Maxicuma® is a patented product (Patent No 512419) bearing Trademark No (1698509). For usage of Maxicuma® in your finished products and licensing the trademarks:

Reach out to us

Patent-&-Trademark-min

For more details on our advanced ingredients
or technology platforms

Get in touch
maxicuma
  • Host of Benefits
  • Turmeric health benefits
  • Accreditations

Technology

  • Green Extraction
  • Liman Technology
  • Cold Water Dispersible

Science

  • Pharmacokinetic Study
  • Preclinical Study
  • Joint Health

Benefits

  • Dosing Benefits
  • Better Value Proposition
  • Applications
  • Self-GRAS Affirmed
  • Patents & Trademark

Newsroom

  • Events
  • Media & Publication
  • Podcasts
  • Blog
Footer-Logo-min

Copyright © 2024. ennaturebiopharma. All Rights Reserved.